Author

M. Manyak

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

D. Gan· 1 shared J. C. Javitt· 1 shared J. Li· 1 shared M. T. Sapko· 1 shared R. Panicucci· 1 shared S. Murphy· 1 shared S. Rahmy· 1 shared X. Lu· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

D. Gan

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

NRX-101 (D-Cycloserine + Lurasidone) , a Qualified Infectious Disease Product, is Active Against Drug-Resistant Urinary Pathogens In Vitro

M. T. Sapko, M. Manyak, R. Panicucci, J. C. Javitt

This study evaluates NRX-101, a combination of D-Cycloserine and lurasidone, against drug-resistant urinary pathogens in vitro, showing DCS's antibacterial activity and lurasidone's lack of interference.

bioRxiv · Jan 14, 2024 · PreprintMicrobiology

Overcome Prostate Cancer Resistance to Immune Checkpoint Therapy with Ketogenic Diet-Induced Epigenetic Reprogramming

S. Murphy, S. Rahmy, D. Gan, Y. Zhu, M. Manyak, J. Li, X. Lu, X. Lu

This study shows that combining ketogenic diet and HDAC inhibitors with ICB therapy enhances anti-tumor effects in prostate cancer by modulating epigenetic and immune mechanisms.

bioRxiv · Aug 7, 2023 · PreprintCancer Biology